Human CD80 / B7-1 Protein
B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7
- 100ug (NPP1183) Please inquiry
Catalog Number | P10698-HCCH |
---|---|
Organism Species | Human |
Host | Human Cells |
Synonyms | B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7 |
Molecular Weight | The mature recombinant human B7-1 consists of 214 amino acids and predicts a molecular mass of 25.5 kDa. As a result of glycosylation, rhB7-1 migrates as approximately 45 kDa band in SDS-PAGE. |
predicted N | Val 35 |
SDS-PAGE | |
Purity | > 85 % as determined by SDS-PAGE |
Protein Construction | The mature form of human B7-1 (NP_005182.1) extracellular domain (Met 1-Asn 242) with five amini acids (DDDDK) at the C-terminus was expressed and purified. |
Bio-activity | |
Research Area | Developmental Biology |Embryogenesis |Germ Layer Formation |Ectoderm Marker |
Formulation | Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
Background | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. |
Reference |